South Korea · Delayed Price · Currency is KRW BioSmart Statistics
Total Valuation
BioSmart has a market cap or net worth of KRW 111.84 billion. The enterprise value is 192.31 billion.
| Market Cap | 111.84B |
| Enterprise Value | 192.31B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioSmart has 25.27 million shares outstanding. The number of shares has increased by 19.40% in one year.
| Current Share Class | 25.27M |
| Shares Outstanding | 25.27M |
| Shares Change (YoY) | +19.40% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 24.54% |
| Owned by Institutions (%) | 5.68% |
| Float | 18.81M |
Valuation Ratios
The trailing PE ratio is 12.43.
| PE Ratio | 12.43 |
| Forward PE | n/a |
| PS Ratio | 0.23 |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 4.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.69, with an EV/FCF ratio of -20.97.
| EV / Earnings | 21.35 |
| EV / Sales | 0.40 |
| EV / EBITDA | 6.69 |
| EV / EBIT | 9.03 |
| EV / FCF | -20.97 |
Financial Position
The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.71 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 2.52 |
| Debt / FCF | -8.28 |
| Interest Coverage | 7.93 |
Financial Efficiency
Return on equity (ROE) is 5.19% and return on invested capital (ROIC) is 6.49%.
| Return on Equity (ROE) | 5.19% |
| Return on Assets (ROA) | 4.95% |
| Return on Invested Capital (ROIC) | 6.49% |
| Return on Capital Employed (ROCE) | 10.32% |
| Weighted Average Cost of Capital (WACC) | 6.41% |
| Revenue Per Employee | 2.86B |
| Profits Per Employee | 53.31M |
| Employee Count | 169 |
| Asset Turnover | 1.69 |
| Inventory Turnover | 7.73 |
Taxes
In the past 12 months, BioSmart has paid 5.74 billion in taxes.
| Income Tax | 5.74B |
| Effective Tax Rate | 38.97% |
Stock Price Statistics
The stock price has increased by +44.35% in the last 52 weeks. The beta is 0.90, so BioSmart's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +44.35% |
| 50-Day Moving Average | 4,655.50 |
| 200-Day Moving Average | 3,607.55 |
| Relative Strength Index (RSI) | 49.70 |
| Average Volume (20 Days) | 408,496 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSmart had revenue of KRW 482.78 billion and earned 9.01 billion in profits. Earnings per share was 356.00.
| Revenue | 482.78B |
| Gross Profit | 85.26B |
| Operating Income | 22.66B |
| Pretax Income | 14.72B |
| Net Income | 9.01B |
| EBITDA | 30.10B |
| EBIT | 22.66B |
| Earnings Per Share (EPS) | 356.00 |
Balance Sheet
The company has 39.11 billion in cash and 75.92 billion in debt, with a net cash position of -36.81 billion or -1,456.33 per share.
| Cash & Cash Equivalents | 39.11B |
| Total Debt | 75.92B |
| Net Cash | -36.81B |
| Net Cash Per Share | -1,456.33 |
| Equity (Book Value) | 187.66B |
| Book Value Per Share | 5,668.41 |
| Working Capital | 63.99B |
Cash Flow
In the last 12 months, operating cash flow was 24.07 billion and capital expenditures -33.24 billion, giving a free cash flow of -9.17 billion.
| Operating Cash Flow | 24.07B |
| Capital Expenditures | -33.24B |
| Depreciation & Amortization | 7.44B |
| Net Borrowing | 21.23B |
| Free Cash Flow | -9.17B |
| FCF Per Share | -362.90 |
Margins
Gross margin is 17.66%, with operating and profit margins of 4.69% and 1.87%.
| Gross Margin | 17.66% |
| Operating Margin | 4.69% |
| Pretax Margin | 3.05% |
| Profit Margin | 1.87% |
| EBITDA Margin | 6.23% |
| EBIT Margin | 4.69% |
| FCF Margin | n/a |
Dividends & Yields
BioSmart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.40% |
| Shareholder Yield | -19.40% |
| Earnings Yield | 8.06% |
| FCF Yield | -8.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2010. It was a reverse split with a ratio of 0.16667.
| Last Split Date | Sep 20, 2010 |
| Split Type | Reverse |
| Split Ratio | 0.16667 |
Scores
BioSmart has an Altman Z-Score of 2.7 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.7 |
| Piotroski F-Score | 5 |